echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > European Radiology: How to shorten whole-body MRI imaging to detect bone metastases and myeloma?

    European Radiology: How to shorten whole-body MRI imaging to detect bone metastases and myeloma?

    • Last Update: 2023-01-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In recent years, whole-body magnetic resonance imaging (WB-MRI) has shown high diagnostic performance and has now been recommended by clinical guidelines for the detection and follow-up of bone lesions in patients with solid tumors and multiple myeloma (MM) metastases
    .
    Standard WB-MRI combines anatomical T1
    , STIR sequences, and functional diffusion-weighted imaging (DWI) sequences
    .
    T1 is the reference sequence for bone marrow lesion detection and characterization
    , and STIR increases the sensitivity
    of lesion detection.
    Due to the high contrast of lesions to background, DWI sequences add diagnostic value to anatomical sequences and extend cancer screening to lymph nodes and extraskeletal organs
    .
    The limitation of WB-MRI is its duration, so
    various measures have been taken clinically to speed up different sequences
    .

    The Dixon technique relies on a chemical shift between protons of water and fat and breaks down the signals of the two components in the
    same voxel.
    The Dixon sequence produces four types of images: in-phase (IP) (equivalent to non-fat inhibited anatomical images), non-in-phase (OP), water images (equivalent to fat suppression), and fat images (equivalent to water suppression).

    A single T2 Dixon sequence combines information similar to STIR (due to water images) and T1-like information (due to fat images).

    The diagnostic performance of the T2 Dixon sequence in detecting metastatic and MM lesions and its ability to replace the T1+STIR sequence has been demonstrated
    in spinal MRI.

    A study published today in the journal European Radiology compared the diagnostic accuracy
    of a single T2 Dixon sequence and a T1+STIR combination as an anatomical sequence used to detect tumor bone marrow lesions in a whole-body MRI (WB-MRI) examination.

    This study prospectively looked at 72 patients (55 men, 17 women, median age = 66 years) with serial solid tumors (prostate, breast, neuroendocrine) high-risk metastases or confirmed multiple myeloma (MM) between January 2019 and January 2020 WB-MRI was performed, including coronal T1, STIR, T2 Dixon, and axial diffusion-weighted imaging sequences
    .
    Two radiologists independently evaluated the combination of T1+STIR sequence and the fat + water reconstruction
    of the T2 Dixon sequence.
    The reference standard was determined by consistent reading of WB-MRI and contemporaneous imaging at baseline and at 6 months
    .
    The repeatability and reproducibility of MRI scores (presence and semi-quantitative counts of lesions), image quality (SNR: signal-noise, CNR: contrast-noise, CRR: contrast-reference ratio), and diagnostic features (Se: sensitivity, Sp: specificity, Acc: accuracy) were evaluated
    for each bone region and each patient.

    Repeatability and reproducibility were good regardless of score, region, and protocol (0.
    67 ≤ AC1 ≤ 0.
    98).

    T2 Dixon fat had a higher CRR compared to T1 (p < 0.
    0001);
    T2 Dixon water had a higher CRR compared to STIR (p = 0.
    0128).

    In each patient analysis,
    the T2 Dixon fat + water Acc of the advanced reader was higher than the Acc of T1 + STIR (Acc = +0.
    027 [+0.
    025; +0.
    029], p < 0.
    0001),
    while Acc was lower for beginner readers (Acc = -0.
    029 [-0.
    031; -0.
    027], p < 0.
    0001).


    Figure consistency
    between metastatic sequences.
    WB-MRI study
    in a 46-year-old patient with metastatic neuroendocrine cancer.
    Two metastases were observed on the L1 vertebral body (arrow) and the right side of the sacrum (arrow
    ).

    Coronal T1(A) and STIR(B)WB-MRI images show both lesions
    .
    The reconstruction of fat (C) and water (D) collected by TSE T2 Dixon showed the same lesions
    .
    Based on the interpretation of all MR images and contemporaneous imaging studies, the reference standard confirmed the presence of two metastases
    .
    E Simultaneous DWI images (b=1000s
    mm-2, inverted grayscale) confirmed the presence of both lesions and did not show additional lesions
    .
    F Gallium-68 PET/CT fusion images showing the same two lesions showing tracer uptake

    This study in patients with bone metastases or MM showed that shorter WB-MRI protocols relying on a single T2 Dixon sequence with fat and water reconstruction can replace the reference T1+STIR sequence for bone screening, resulting in shorter examination times without loss of diagnostic accuracy
    .

    Original source:

    Ophelye Chiabai,Sandy Van Nieuwenhove,Marie-Christiane Vekemans,et al.
    Whole-body MRI in oncology: can a single anatomic T2 Dixon sequence replace the combination of T1 and STIR sequences to detect skeletal metastasis and myeloma?
    DOI:10.
    1007/s00330-022-09007-8

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.